Eli Lilly presents positive data from tirzepatide sub-studies

Substudies connected to Eli Lilly's Supass 3 phase III trial have generated favorable results for the candidate when compared to Novo Nordisk's long-acting insulin Tresiba
Photo: Mike Blake/Reuters/Ritzau Scanpix
Photo: Mike Blake/Reuters/Ritzau Scanpix
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN

US-based pharmaceutical company Eli Lilly has presented several positive results for the drug candidate tirzepatide, which is a combination of the two hormones known respectively as GLIP-1 and GIP, at the annual meeting of the European Association for the Study of Diabetes (EASD). The company reports this in two seperate press releases on Thursday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading